Company intelligence
cAMPfield Therapeutics
Redefining the treatment of inflammatory diseases.
Biotechnology Research
San Diego, US
21 employees
2 public signals
Verified activity
Signals from cAMPfield Therapeutics
2 published signals
Research & Knowledge
cAMPfield Therapeutics announced the results of the PHocus PH 2 study, showing a 56% reduction in PVR, 35m 6MWD at 16 weeks, 52m at week 24, 53% reduction in NT-proBNP, and very well tolerated results.
Reported by Bill Gerhart
Research & Knowledge
cAMPfield Therapeutics announced positive results from a phase 2a phosphorus activity trial.
Reported by Bill Gerhart